The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Try the newly designed Company Pages!
Switch now

Incyte Corporation

  • INCY
  • NASDAQ
  • Consumer Products
  • Latest 72.27
  • Currency US$
  • Change 0.66
  • Percent Change 0.922 %
  • Volume 725,012
  • Fri Nov 21, 2014 04:00 PM EST NASDAQ data delayed 15 minutes.
  • Open 72.50
  • Previous Close 71.61
  • High 73.15
  • Low 71.64
  • Bidx0 0.0000
  • Askx0 0.0000
  • 52-week High11/21 73.15
  • 52-week Low04/15 40.30
  • Beta 0.868
  • Market Cap 11,963.58M
  • EPS -0.37
  • P/E
  • Forward P/E 277.96
  • PEG
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $373,660,000
  • Earnings $-101,440,000
  • Return on Equity n/a

Cash Flow

  • Cash Flow --
  • Cash $436,580,000
  • Current Ratio 5.43

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $666,820,000
  • Liabilities $829,240,000
  • Liabilities-to-Equity Ratio n/a

Price Ratios

  • Price to Sales 32.02
  • Price to Book n/a
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Oct 30 $0.02 Feb 11 $-0.11
Surprises Oct 30 1,550.00% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Nov 23, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Incyte Corp is a drug discovery company that is using its expertise in genomics, medicinal chemistry and molecular, cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of new small molecule drugs for cancer and inflammation. Incyte also has strategic alliances with Lexicon Genetics and Medarex focused on the discovery and development of protein therapeutics or antibodies to treat inflammatory diseases and cancer.

Related Securities
Symbol Type Latest % Chg

Officers

  • Richard U. De Schutter Chairman
  • Herve Hoppenot Chief Executive Officer
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

ROUTE 141 & HENRY CLAY ROAD B
WILMINGTON, DE
19880

Phone: (302)-498-6700
Fax: (302)-4252750

pmurphy@incyte.com
www.incyte.com

Ideas & Discussion

Live Discussion of INCY on StockTwits
The Globe and Mail has
updated our Company Pages
Switch to the newly designed Company Pages format today for a more in-depth look at the companies you're following and pages that are easier to navigate. If you prefer the old layout after trying the new Company Pages, you can switch back anytime.